Literature DB >> 16783140

Incidence and prevalence of glaucoma in severe ocular surface disease.

Julie H Tsai1, Elizabeth Derby, Edward J Holland, Anup K Khatana.   

Abstract

PURPOSE: To describe the incidence and prevalence of glaucoma in a patient population with severe ocular surface disease (OSD).
METHODS: A retrospective case series was compiled from all charts of patients in the Cincinnati Eye Institute/University of Cincinnati and University of Minnesota population with a diagnosis of severe OSD from 1991 to 2003. The incidence and prevalence of glaucoma in the overall patient population were identified, and stratified into disease subgroups.
RESULTS: Of the 108 eyes evaluated in this study, 71 were diagnosed with glaucoma. The overall prevalence of glaucoma in patients with severe OSD is 65.7%, with a range from 42.9% to 88.4%. Analysis by subgroup shows the highest percentage of patients with concurrent glaucoma fall into the categories of aniridia and chemical injury, and the lowest was noted in those patients with autoimmune or iatrogenic OSD. Overall, the incidence of glaucoma was 20.4%, with a range of 13.6% to 60%.
CONCLUSIONS: Compared with previous studies, our results show a significantly higher prevalence of glaucoma in patients with severe OSD. This information warrants increased attention to treatment and management of OSD and concurrent glaucoma.

Entities:  

Mesh:

Year:  2006        PMID: 16783140     DOI: 10.1097/01.ico.0000220776.93852.d9

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  27 in total

1.  Glaucoma associated with Boston type I keratoprosthesis.

Authors:  Roheena Kamyar; Jennifer S Weizer; Fernando Heitor de Paula; Joshua D Stein; Sayoko E Moroi; Denise John; David C Musch; Shahzad I Mian
Journal:  Cornea       Date:  2012-02       Impact factor: 2.651

2.  [Preservative-free glaucoma treatment : Selection of the correct treatment in 1 min].

Authors:  S Pfennigsdorf; P Eschstruth
Journal:  Ophthalmologe       Date:  2016-05       Impact factor: 1.059

3.  End-stage glaucoma in Stevens-Johnson syndrome.

Authors:  Kenya Yuki; Shigeto Shimmura; Daisuke Shiba; Kazuo Tsubota
Journal:  Jpn J Ophthalmol       Date:  2009-01-30       Impact factor: 2.447

4.  Intraocular pressure control with Ahmed glaucoma drainage device in patients with cicatricial ocular surface disease-associated or aniridia-related glaucoma.

Authors:  Radwan Almousa; Damian B Lake
Journal:  Int Ophthalmol       Date:  2013-10-18       Impact factor: 2.031

Review 5.  An update on chemical eye burns.

Authors:  Mukhtar Bizrah; Ammar Yusuf; Sajjad Ahmad
Journal:  Eye (Lond)       Date:  2019-05-13       Impact factor: 3.775

6.  Analysis of long-term outcomes for combined pars plana vitrectomy (PPV) and glaucoma tube shunt surgery in eyes with advanced glaucoma.

Authors:  A Gandhi; D M Miller; J M Zink; A K Khatana; C D Riemann; M R Petersen; R E Foster; R A Sisk
Journal:  Eye (Lond)       Date:  2013-12-13       Impact factor: 3.775

7.  Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy.

Authors:  Y Kitazawa; P Smith; N Sasaki; S Kotake; K Bae; Y Iwamoto
Journal:  Eye (Lond)       Date:  2011-06-24       Impact factor: 3.775

8.  Clinical characteristics of patients hospitalized for ocular chemical injuries in Shanghai from 2012 to 2017.

Authors:  Tao Li; Bo Jiang; Xiaodong Zhou
Journal:  Int Ophthalmol       Date:  2020-01-09       Impact factor: 2.031

9.  Prevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-host disease.

Authors:  Ujwala S Saboo; Francisco Amparo; Hasanain Shikari; Reza Dana
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-12       Impact factor: 3.117

Review 10.  Current and Upcoming Therapies for Ocular Surface Chemical Injuries.

Authors:  Alireza Baradaran-Rafii; Medi Eslani; Zeeshan Haq; Ebrahim Shirzadeh; Michael J Huvard; Ali R Djalilian
Journal:  Ocul Surf       Date:  2016-09-17       Impact factor: 5.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.